for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Abcam Plc

ABCA.L

現在値

1,254.00GBp

変化

-200.00(-13.76%)

出来高

580,897

本日のレンジ

1,246.00

 - 

1,432.00

52週レンジ

1,013.57

 - 

1,760.00

∙ 約20分前の相場を表示しています。

適時開示

ABCAM Plc Announces 20% Constant Exchange Rate Revenue Growth In H1

Sept 12 (Reuters) - Abcam PLC <ABCA.L>::ABCAM PLC H1 ADJUSTED DILUTED EARNINGS PER SHARE 14.0 PENCE.ABCAM PLC - 20% CONSTANT EXCHANGE RATE REVENUE GROWTH IN H1.ABCAM PLC - SEES FY TOTAL REVENUE TO INCREASE APPROXIMATELY 20% CER INCLUDING IMPACT FROM ACQUISITION OF BIOVISION.

Cambridge Biotech Abcam To Abandon London Listing For Nasdaq - FT

July 20 (Reuters) - :CAMBRIDGE BIOTECH ABCAM TO ABANDON LONDON LISTING FOR NASDAQ - FT.

Abcam Expects To Report Total Revenues For Six-Month Period Of About £185 Mln

July 20 (Reuters) - Abcam PLC <ABCA.L>::ABCAM PLC - TRADING STATEMENT.GROUP EXPECTS TO REPORT TOTAL REVENUES FOR SIX-MONTH PERIOD OF APPROXIMATELY £185 MLN.DECIDED TO PURSUE A PROPOSAL TO MAINTAIN A SOLE LISTING ON NASDAQ AND THEREFORE TO CANCEL ADMISSION OF COMPANY'S SHARES TO TRADING ON AIM.SEES CY22 TOTAL CER REVENUE GROWTH OF APPROXIMATELY 20% (INCLUDING BIOVISION) WITH MID-TEENS ORGANIC CER REVENUE GROWTH.

Abcam Plc FY Statutory Reported Oper Profit £7.1 Mln

March 14 (Reuters) - Abcam PLC <ABCA.L>::ABCAM PLC: FY STATUTORY REPORTED OPERATING PROFIT INCREASED TO £7.1M FROM £1.0M IN CY2020.ABCAM PLC: FY REVENUE GROWTH OF +22% (+17% REPORTED) AT CONSTANT EXCHANGE RATES, COMPARED TO CY2020.ABCAM PLC: CY2022 TRADING PERFORMANCE YTD IS IN LINE WITH OUR EXPECTATIONS.ABCAM PLC - CY2024 REVENUE GOAL TARGET RANGE INCREASED BY £25M TO £450M-£525M.ABCAM PLC: EXPECT TOTAL CER REVENUE GROWTH OF C.20% (INCLUDING BIOVISION) WITH MID-TEENS ORGANIC CER REVENUE GROWTH FOR CY2022.ABCAM PLC - EXPECT TOTAL ADJUSTED OPERATING COST GROWTH (INCLUDING DEPRECIATION AND AMORTISATION) AT MID-TEENS PERCENTAGE FOR CY2022.

Abcam Collaborates With Twist Bioscience To Enhance Antibody Discovery

Feb 1 (Reuters) - Abcam PLC <ABCA.L>::ABCAM COLLABORATES WITH TWIST BIOSCIENCE TO ENHANCE ANTIBODY DISCOVERY FOR DIAGNOSTIC AND RESEARCH APPLICATIONS.ABCAM PLC: ABCAM TO LICENSE IN VHH PHAGE LIBRARY((1)) FROM TWIST, COMPLEMENTING IN-HOUSE RECOMBINANT ANTIBODY CAPABILITIES.ABCAM PLC: ABCAM TO DEVELOP AND COMMERCIALIZE ANTIBODIES FOR DIAGNOSTIC AND RESEARCH USE, WITH TWIST RETAINING RIGHTS FOR THERAPEUTIC APPLICATIONS.

Abcam Sees FY Adj Oper Profit In Line With Board's Expectations

Jan 27 (Reuters) - Abcam PLC <ABCA.L>::ABCAM PLC - TRADING STATEMENT.ABCAM PLC - EXPECTS TO REPORT TOTAL REVENUES FOR 12 MONTHS ENDED 31 DECEMBER 2021 OF APPROXIMATELY £315 MILLION,.ABCAM PLC - ANTICIPATE ADJUSTED OPERATING PROFITS WILL BE REPORTED IN LINE WITH BOARD'S EXPECTATIONS FOR FY.ABCAM PLC - FULL RESULTS FOR 18 MONTH PERIOD ENDED 31 DECEMBER 2021 WILL BE RELEASED ON 14 MARCH 2022..ABCAM PLC - REMAIN ON TRACK TO ACHIEVE OUR FINANCIAL GOALS FOR FIVE YEAR PLAN ENDING IN 2024..

Abcam Says Forex Headwind To HY Rev Growth Is Expected To Be About 6%

Sept 13 (Reuters) - Abcam PLC <ABCA.L>::H2 OPERATING PROFIT 10.3 MILLION STG VERSUS -16.1 MILLION STG LOSS YEAR AGO.H2 ADJUSTED OPERATING PROFIT ROSE 78 PERCENT TO 19.8 MILLION STG.TRADING PERFORMANCE YEAR-TO-DATE IS IN LINE WITH BOARD'S EXPECTATIONS, WITH MID-TEENS CER REVENUE GROWTH IN JULY AND AUGUST.FOREIGN EXCHANGE HEADWIND TO REVENUE GROWTH IS EXPECTED TO BE APPROXIMATELY 6% IN SIX MONTHS TO 31 DECEMBER 2021.REMAIN COMMITTED TO GENERATING REVENUE OF £425 - 500M FOR YEAR ENDING 31 DECEMBER 2024.ABCAM - LABORATORY ACTIVITY AND DEMAND HAVE CONTINUED TO GRADUALLY RECOVER AND TRADING PERFORMANCE YEAR-TO-DATE IS IN LINE WITH BOARD'S EXPECTATIONS.COMMITTED TO GENERATING REVENUE OF £425 - 500M FOR YEAR ENDING 31 DECEMBER 2024.ADJUSTED DEPRECIATION AND AMORTISATION ('D&A') COSTS OF APPROXIMATELY £17-18M ARE EXPECTED IN SIX MONTHS TO 30 DECEMBER 2021.EXCLUDING D&A, ADJUSTED COSTS AND EXPENSES FOR HY ENDED 31 DEC EXPECTED TO GROW AT MID- TO HIGH- SINGLE DIGIT OVER HY ENDED 30 JUNE 2021.

Abcam Says Sally W Crawford Appointed Non-Exec Director

Aug 13 (Reuters) - Abcam PLC <ABCA.L>::ABCAM PLC - DIRECTORATE CHANGE.APPOINTMENT OF SALLY W. CRAWFORD AS A NON-EXECUTIVE DIRECTOR .

Boai NKY Medical To Sell BioVision To Abcam

Aug 2 (Reuters) - Boai NKY Medical Holdings Ltd <300109.SZ>::SAYS UNIT AGREES TO SELL SPV THAT OWNS BIOVISION TO ABCAM US BY CASH.BOAI NKY MEDICAL SAYS BASIC VALUE FOR ITS SPV NKY US IS $342.9 MILLION.SAYS IT SIGNS STRATEGIC MOU WITH ABCAM PLC <<<ABCA.L>>>.

Abcam Plc Says HY Underlying Trading Modestly Ahead Of Board's Expectations

July 1 (Reuters) - Abcam PLC <ABCA.L>::ABCAM PLC - PRE-CLOSE TRADING UPDATE.ABCAM PLC - HY UNDERLYING TRADING HAS BEEN MODESTLY AHEAD OF BOARD'S EXPECTATIONS AND IN LINE WITH EXPECTATIONS AFTER CURRENCY MOVEMENTS.

金融情報はリフィニティブから。すべての情報は少なくとも20分遅れで表示されています。

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up